- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 7,238
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- DS-1062a, Docetaxel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Anaheim, California • Glendale, California + 28 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 13 more
- Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten (5 - 20 mg)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more
- Conditions
- Acute ST Elevation Myocardial Infarction
- Interventions
- Epoetin alfa
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 16
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 11 more
- Conditions
- Chronic Pain, Neck Pain, Back Pain
- Interventions
- Cognitive Behavioral Therapy, Acceptance and Commitment Therapy, Emotional Awareness and Expression Therapy, Treatment as Usual
- Behavioral · Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Detroit, Michigan
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Olaparib, Ramucirumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 32
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 24 more
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Interventions
- FOCUS-Web
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan
- Conditions
- Urinary Tract Infections
- Interventions
- Bladder Stimulation technique
- Other
- Lead sponsor
- Children's Hospital of Michigan
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Oral Mucositis
- Interventions
- Clonidine Lauriad® 50µg, Clonidine Lauriad® 100µg, Placebo Lauriad®
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 19
- States / cities
- Sun City, Arizona • Corona, California • Duarte, California + 16 more
- Conditions
- Cancer
- Interventions
- dalteparin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Pleasant Hill, California • Torrance, California + 18 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- cytogenetic analysis, fluorescence in situ hybridization
- Genetic
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 3,341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2012
- U.S. locations
- 280
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma, Unresectable Cutaneous Melanoma, Unresectable Melanoma
- Interventions
- Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 638
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 392 more
- Conditions
- Epilepsies, Partial
- Interventions
- Lyrica (pregabalin), placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 103
- States / cities
- Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 43 more
- Conditions
- HIV Infections
- Interventions
- Saquinavir, Zalcitabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 41
- States / cities
- Harbor City, California • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- Breast Cancer
- Interventions
- axillary lymph node dissection, whole breast irradiation
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 116 more
- Conditions
- Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
- Interventions
- KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel
- Biological · Drug
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 11 more
- Conditions
- Acne Vulgaris, Acne
- Interventions
- CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 506
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Lung Cancer
- Interventions
- MEDI4736, tremelimumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Ramucirumab, Docetaxel, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 33
- States / cities
- Fayetteville, Arkansas • Fullerton, California • Los Angeles, California + 28 more
- Conditions
- Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas, Cancer of the Pancreas, Metastases, Metastatic Cancer, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Cancer, Bone Metastases, Endocrine Cancer, Oncology, Oncology Patients, Solid Tumors, Advanced Malignancy
- Interventions
- AMG 479, Placebo, gemcitabine
- Drug
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 24
- States / cities
- Fullerton, California • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Cardiovascular Risk, Chronic Kidney Disease, Inflammation
- Interventions
- Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more